Recently Released Market Study: GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint

New York, NY -- (SBWIRE) -- 09/05/2013 -- Agenus Inc., (NASDAQ:AGEN) a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s MAGE-A3 vaccine failed to help skin-tumor patients in a trial.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.